ATE288749T1 - Verwendung von kannabidiol als entzündunghemmende mittel - Google Patents

Verwendung von kannabidiol als entzündunghemmende mittel

Info

Publication number
ATE288749T1
ATE288749T1 AT99915942T AT99915942T ATE288749T1 AT E288749 T1 ATE288749 T1 AT E288749T1 AT 99915942 T AT99915942 T AT 99915942T AT 99915942 T AT99915942 T AT 99915942T AT E288749 T1 ATE288749 T1 AT E288749T1
Authority
AT
Austria
Prior art keywords
cannabidiol
inflammatory agents
cannabinoids
inflammatory diseases
treating inflammatory
Prior art date
Application number
AT99915942T
Other languages
English (en)
Inventor
Marc Feldmann
Anne-Marie Malfait
Ruth Gallily
Raphael Mechoulam
Original Assignee
Kennedy Rheumatology Inst
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Rheumatology Inst, Yissum Res Dev Co filed Critical Kennedy Rheumatology Inst
Application granted granted Critical
Publication of ATE288749T1 publication Critical patent/ATE288749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99915942T 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel ATE288749T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807639.1A GB9807639D0 (en) 1998-04-14 1998-04-14 Anti-inflammatory agents
PCT/GB1999/001140 WO1999052524A1 (en) 1998-04-14 1999-04-14 Use of cannabinoids as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ATE288749T1 true ATE288749T1 (de) 2005-02-15

Family

ID=10830115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915942T ATE288749T1 (de) 1998-04-14 1999-04-14 Verwendung von kannabidiol als entzündunghemmende mittel

Country Status (12)

Country Link
US (1) US6410588B1 (de)
EP (1) EP1071417B1 (de)
JP (1) JP2002511411A (de)
AT (1) ATE288749T1 (de)
AU (1) AU757945B2 (de)
CA (1) CA2328368C (de)
DE (1) DE69923671T2 (de)
DK (1) DK1071417T3 (de)
ES (1) ES2241277T3 (de)
GB (1) GB9807639D0 (de)
IL (1) IL138979A0 (de)
WO (1) WO1999052524A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
BR0009200A (pt) * 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
HUP0600031A3 (en) * 2000-10-31 2012-02-28 Pharma Mar Kahalalide formulations and their use
EP1206934A1 (de) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade von Natriumkanälen mit Phenolderivaten
US10004684B2 (en) 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
GB0202385D0 (en) * 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (de) * 2002-02-01 2019-05-08 GW Pharma Limited Zusammensetzungen mit cannabidiolsäure zur behandlung von übelkeit, erbrechen, emesis, reisekrankheit oder ähnlichen zuständen
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
PT1542657E (pt) * 2002-08-14 2012-02-29 Gw Pharma Ltd Formulações líquidas canabinóides para administração pela mucosa
US7067155B2 (en) * 2003-01-03 2006-06-27 Tbni, Inc. Anti-inflammatory humate compositions and methods of use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
EP2007376B1 (de) 2006-03-13 2013-05-08 Hadasit Medical Research Services And Development Ltd. Therapeutische verwendungen von cannabidiol-verbindungen
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
GB2450741A (en) * 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
DE602007011766D1 (de) * 2007-10-02 2011-02-17 Vivacell Biotechnology Espana S L Zusammensetzung mit nicht-psychotropen Cannabinoiden zur Behandlung von Entzündungserkrankungen
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
US9889100B2 (en) 2013-05-02 2018-02-13 Mor Research Applications Ltd. Cannabidiol for treatment of severe and refractory graft-versus-host disease
US9956182B2 (en) 2013-05-02 2018-05-01 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
EP3277260B1 (de) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Pflanzenextrakte aus erodium crassifolium l'her und verwendungen davon
US12303541B2 (en) 2015-04-01 2025-05-20 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium L'Her plant extracts and uses thereof
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20180296521A1 (en) * 2015-10-16 2018-10-18 Scythian Biosciences Inc. Methods and compositions for treating gastrointestinal inflammation
WO2017160923A1 (en) * 2016-03-15 2017-09-21 Royal Oil Colorado Llc Formulations of argan oil and cannabidiol
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10399920B2 (en) 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
GB2551985B (en) * 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CA3077624A1 (en) 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
JP2019533731A (ja) 2016-11-02 2019-11-21 ティーオー ファーマスーティカルズ リミテッド ライアビリティー カンパニーＴＯ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＬＬＣ Ｃｂｄとコパキソンの併用療法
CN110621312A (zh) 2017-03-05 2019-12-27 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 用于治疗癌症的组合物和方法
US11666542B2 (en) * 2017-07-18 2023-06-06 Deyi Pharmarmaceutical Ltd. Use of cannabidiol in treatment of pulmonary hypertension
WO2019034985A1 (en) * 2017-08-14 2019-02-21 Zynerba Pharmaceuticals, Inc. METHODS OF TREATING ARTHROSIS USING CANNABIDIOL TRANSDERMAL GEL
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
EP3801028A4 (de) 2018-05-30 2022-04-13 Direct Biologics LLC Gefrorenes oder pulverförmiges wachstumsfaktor- und extrazelluläre-vesikel-additiv mit einem präparat aus mesenchymalen stammzellen (msc) und verwendungsverfahren
WO2020081513A1 (en) * 2018-10-16 2020-04-23 Systamedic Inc. Novel compositions for the treatment of inflammatory diseases
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
EP3888649B1 (de) * 2019-01-24 2023-08-09 Hanyi Bio-Technology Company Ltd. Cannflavin a zur verwendung bei der förderung der wundheilung und behandlung oder vorbeugung von diabetischen füssen
EP3920946A4 (de) 2019-02-07 2022-11-09 Direct Biologics LLC Verfahren zur behandlung von osteoarthritis mit einer kombination ausn mesenchymalen stammzellexosomen, mesenchymalen stammzellen aus der synovia und gerüsten
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide
EP3962296B1 (de) 2019-04-30 2026-04-29 Greenway Herbal Products, LLC Cannabinoidzusammensetzungen und verfahren zur verwendung
CA3146433A1 (en) * 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
IL296943A (en) * 2020-04-02 2022-12-01 Incannex Healthcare Ltd Methods and compositions for treating or preventing an inflammatory condition
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
AU2021270970A1 (en) * 2020-05-11 2022-12-15 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
JP2023534362A (ja) * 2020-05-11 2023-08-09 アド アドヴァンスト ドラッグ デリヴァリー テクノロジーズ リミテッド カンナビノイドの使用および製剤
CA3199891A1 (en) 2020-11-24 2022-06-02 Ruth Gallily Cannabinoid derivatives and their use for the treatment of inflammation and/or pain and/or obesity
WO2023283684A1 (en) * 2021-07-15 2023-01-19 Incannex Healthcare Limited Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule
CA3236951A1 (en) * 2021-11-27 2023-06-01 Jonnie R. Williams Synthetic cannabinoid compounds, pharmaceutical compositions, and treatment methods
CA3244798A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
EP4230201A1 (de) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
EP4568702A1 (de) 2022-08-12 2025-06-18 Jazz Pharmaceuticals Research UK Limited Feste orale darreichungsformen mit cannabinoiden
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025259202A1 (en) * 2024-06-12 2025-12-18 Chiang Mai University A method of reprogramming human somatic cells and reprogrammed cells derived thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48824A (en) 1976-01-12 1980-05-30 Yissum Res Dev Co Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4847290A (en) * 1987-08-17 1989-07-11 Sumner Burstein Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
US4973603A (en) * 1988-06-16 1990-11-27 Sumner Burstein Platelet activating factor antagonist and methods of use therefor
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics

Also Published As

Publication number Publication date
CA2328368A1 (en) 1999-10-21
WO1999052524A1 (en) 1999-10-21
JP2002511411A (ja) 2002-04-16
DE69923671D1 (de) 2005-03-17
EP1071417A1 (de) 2001-01-31
US6410588B1 (en) 2002-06-25
DK1071417T3 (da) 2005-06-13
ES2241277T3 (es) 2005-10-16
CA2328368C (en) 2009-03-31
DE69923671T2 (de) 2006-03-16
GB9807639D0 (en) 1998-06-10
AU3436199A (en) 1999-11-01
IL138979A0 (en) 2001-11-25
AU757945B2 (en) 2003-03-13
EP1071417B1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
DK0882021T3 (da) Nye phenanthridiner
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
MY138883A (en) Use of asiatic acid for treatment of cencer
DE69011305D1 (de) Cyclopropylderivate als Lipoxygenase-Inhibitoren.
NO994330L (no) Metode for behandling av en tumor
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
FR2815859B1 (fr) Utilisation de l'association d'au moins un carotenoide a activite provitaminique a et d'au moins un carotenoide sans activite provitaminique a pour traiter les signes du vieillissement
BG101126A (en) The use of muramylpeptide compounds
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69905602D1 (de) Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
RU94024337A (ru) Антиметастатическое средство
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
CO5271719A1 (es) Composicion cosmetica adelgazante que contienen una substancia inductora de la produccion de il-6
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
GEP20012408B (en) Means for Treatment of Psoriasis
ECSP992841A (es) Nuevos derivados del acido dihidroxihexanoico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties